Prepaids and Other Assets |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prepaids and Other Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prepaids and Other Assets | 5. Prepaids and Other Assets Prepaid expenses and other current assets consisted of the following (in thousands):
As of June 30, 2025 and December 31, 2024, the Company had restricted cash of $0.3 million held as a letter of credit for the benefit of a clinical research organization. The related letter of credit was classified within other non-current assets on the condensed consolidated balance sheet as of June 30, 2025 and December 31, 2024. As of June 30, 2025, the Company also had $8.3 million in long-term prepayments, made in conjunction with the Company's research and development activities, classified within other non-current assets. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||